Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 5Phase 1 5Phase 1/2 3

Status

Active not recruiting 3Recruiting 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 5Prostatic Neoplasms 2Neoplasm Metastasis 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Disease Progression 2Triple Negative Breast Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1

Interventions

Cyclophosphamide 149Docetaxel 138Paclitaxel 127Trastuzumab 119Tamoxifen 110Capecitabine 104Letrozole 92Epirubicin 79Doxorubicin 70Anastrozole 70exemestane 67Fulvestrant 65Fluorouracil 61Radiotherapy 60pertuzumab 40Gemcitabine 39Carboplatin 38Vinorelbine 34Goserelin 34Bevacizumab 29Zoledronic Acid 28Methotrexate 28Chemotherapy, Adjuvant 28eribulin 27Lapatinib 25ribociclib 24palbociclib 24Drug Therapy 22130-nm albumin-bound paclitaxel 20pegfilgrastim 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms × capivasertib × Clear all
NCT06982521 2026-05-08

ReDiscover-2

Relay Therapeutics, Inc.

Phase 3 Recruiting
540 enrolled
Breast

Breast Neoplasms

NCT06764186 2026-04-08

CAPItana

AstraZeneca

Phase 3 Active not recruiting
101 enrolled
Breast

Breast Neoplasms

NCT06635447 2026-03-27

CAPItrue

AstraZeneca

Phase 3 Active not recruiting
258 enrolled
Breast

Breast Neoplasms, Disease Progression

NCT07281833 2026-02-27

CAPIcorn

West German Study Group

Phase 3 Recruiting
250 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Disease Progression

NCT03997123 2025-12-22

CAPItello-290

AstraZeneca

Phase 3 Active not recruiting
923 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡